GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » Change In Inventory

Rigel Pharmaceuticals (Rigel Pharmaceuticals) Change In Inventory : $1.2 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals Change In Inventory?

Rigel Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2023 was $2.5 Mil. It means Rigel Pharmaceuticals's inventory declined by $2.5 Mil from Sep. 2023 to Dec. 2023 .

Rigel Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $1.2 Mil. It means Rigel Pharmaceuticals's inventory declined by $1.2 Mil from Dec. 2022 to Dec. 2023 .

Rigel Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2023 was $5.5 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Rigel Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 was 140.05.

Inventory Turnover measures how fast the company turns over its inventory within a year. Rigel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.65.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Rigel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.16.


Rigel Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Rigel Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Change In Inventory Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.37 -0.13 -4.88 -2.38 1.17

Rigel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.98 -1.95 0.31 0.28 2.53

Rigel Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rigel Pharmaceuticals  (NAS:RIGL) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Rigel Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=5.817/3.79*365 / 4
=140.05

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Rigel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Rigel Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rigel Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Executives
Raul R Rodriguez officer: Sr VP of Bus Dev and Com Ops 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos officer: EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer officer: EVP & CMO 5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno officer: EVP & Chief Financial Officer 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey officer: EVP, GC & Corp Sec 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan officer: Principal Accounting Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii officer: EVP & Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel officer: EVP Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080